Biosign Technologies Announces Granting of Incentive Stock Options

TORONTO, Feb. 2 /CNW/ - Biosign Technologies Inc. (TSXV: BIO, "Biosign") announces the granting of incentive stock options to certain officers, directors, employees, and consultants of the company.

Subject to TSX Venture Exchange approval, Biosign has today granted 3,983,500 incentive stock options pursuant to the Biosign Stock Option Plan. These options will be exercisable at prices of $1.50 and $2.25 per share and will expire on January 24, 2016. One million options vest immediately and the balance over the next 18 months. After today's option grants, a total of 2,774,650 incentive stock options remain available under the Stock Option Plan. Additional information about Biosign can be found in its filings at

About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit

Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Biosign Technologies Inc.

For further information:

Peter Tassiopoulos
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234         
Alan S. Roemer, SVP
The Trout Group LLC
Phone: 646 378-2900

Profil de l'entreprise

Biosign Technologies Inc.

Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.